Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
- Adragos Pharma now third largest pure-play CDMO in the Japanese market
- Long-term agreement with Sanofi secures local healthcare supply
Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest pure-play contract manufacturer in Japan, one of its three core markets. The acquisition also kicks off a long-term supply agreement between the CDMO and Sanofi. Kawagoe Pharma will continue to produce for Sanofi and the Japanese market as a strategic partner, thus playing an essential role for the local healthcare system.
The official handover of the production facility took place yesterday in the presence of the workforce, which will remain at the site, as well as of representatives of both companies.
The Kawagoe site near Tokyo is one of the largest and most technically advanced of its kind in Japan. Under Sanofi, oral solids and ampoules were manufactured here. In addition, the site provided packaging, visual inspection, and QC test services for the Japanese and Asian markets.
Jeremy Goldnadel, International Cluster Head, Manufacturing and Supply, of Sanofi expressed, "I would like, in the name of Sanofi, to express our deepest gratitude to the highly professional employees at the Kawagoe site over our long 50-years history, and looking forward, wish them all the success and bright future at Adragos Pharma. We are convinced that our long-term partnership will ensure the supply of high quality medicines generating the greatest possible benefit for patients in Japan."
Dr. Andreas Raabe, CEO of Adragos Pharma: "With this acquisition, we have taken an important step towards becoming a leading global CDMO. Our goal is to introduce new customers from Europe, North America and the Japanese domestic market to the production site, as well as to further expand the site's services and capabilities for Sanofi and future customers."
Marco Gorgas, CTO at Adragos Pharma, explains, "The site's capabilities and resources provide a solid foundation for future growth. Both Sanofi and our new customers can rely on our full commitment to providing affordable, high-quality products to patients."
The exact terms of the transaction are not disclosed.
About Adragos
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan (as of March 1, 2023).
Here you can find images to download for your story. We are grateful for a publication reference.
Press contact
press@adragos-pharma.com
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
End-to-end digitalization in production: iTAC presents MOM system at HANNOVER MESSE24.3.2023 08:55:32 CET | Press release
The demands for agility and efficiency in manufacturing are increasing. Simultaneously, quality must be maintained at a high level. iTAC Software AG and its parent company Dürr have the answer: a modular all-in-one solution for the planning, execution, control, monitoring, optimization and predictive analysis of manufacturing. The Manufacturing Operations Management (MOM) system is based on end-to-end networking and digitalization. Another special feature is the microservices architecture to provide functionalities tailored to specific requirements. The company will be demonstrating the advantages of this solution at HANNOVER MESSE (hall15, booth E34).
TXOne Networks Widens the Scope of Network Protection for OT Environments with Launch of New Product EdgeIPS 10320.3.2023 09:54:39 CET | Pressemelding
The new model, EdgeIPS 103, offers the latest flexible, transparent network security solution with elevated throughput, smarter, OT native networking security appliances and contingency protocols to protect critical assets in OT environments.
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories20.3.2023 09:43:28 CET | Press release
Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally (Munich / London / Athens) – Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers. Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreemen
Roger Waters: Antisemitism is odious, and I condemn it17.3.2023 09:39:04 CET | Pressemelding
Statement by Roger Waters on antisemitism, his criticism of the Israeli government and freedom of speech.
Roger Waters fights back15.3.2023 09:08:58 CET | Press release
Roger Waters defends freedom of speech and takes legal action against proposed concert cancellations in Frankfurt and Munich.
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom